



Protecting Infants from Respiratory Syncytial Virus (RSV)

Overview

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms but can also affect the lungs. While most children recover from an RSV infection in a week or two, RSV infection can be dangerous for infants and some young children, causing difficulty breathing, low oxygen levels, and dehydration. RSV is the leading cause of infant hospitalizations in the United States. The Centers for Disease Control and Prevention (CDC) recommends two new immunizations to prevent severe RSV disease in infants and older babies.


During this COCA Call, presenters will give a comprehensive overview of CDC's new recommendations to prevent severe RSV disease in infants, including clinical guidance and considerations for administering RSV immunizations to infants and pregnant people during weeks 32 through 36 of pregnancy.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the [COCA Call webpage](#) a few hours after the live event ends.

The slide set will be available on the day of the call on the [COCA Call webpage](#) under Call Materials.

[Free Continuing Education \(CE\)](#) will be offered for this COCA Call.

Registration is not required.



Date: Thursday, October 26, 2023

Time: 2:00 PM – 3:00 PM ET

Webinar Link:

<https://www.zoomgov.com/j/1600578610>

Webinar ID: 161 057 8610

Passcode: 189293

Telephone:

US: +1 669 254 5252 or 1 646 828 7666

One-tap Mobile:

+16692545252,,1600578610#,,,,*189293#
or
+16468287666,,1600578610#,,,,*189293#

[International numbers](#)

Activity-specific Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

1. Review current RSV epidemiology in infants.
2. Describe the safety of nirsevimab and the maternal RSV vaccine.
3. Discuss CDC's latest recommendations and clinical considerations for administering RSV immunizations in infants under 8 months, toddlers at increased risk for severe illness due to RSV, and pregnant people.
4. List implementation considerations for nirsevimab and the maternal RSV vaccine, including updates for the Vaccines for Children (VFC) program.

COCA Call Objectives

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC's role in the topic covered during the presentation.
3. Describe the topic's implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Presenters

Sarah Meyer, MD, MPH

Chief Medical Officer

Immunization Services Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Jefferson Jones, MD, MPH

Co-Lead, ACIP RSV Maternal-Pediatric Work Group

Coronavirus and Other Respiratory Viruses Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention

Instructions for Obtaining Continuing Education

To receive continuing education (CE) for **WC4520-102623**—Clinician Outreach and Communication Activity (COCA) Calls/Webinars – **Protecting Infants from Respiratory Syncytial Virus (RSV), Thursday, October 26, 2023**, please visit [TCEO](#) and follow these [9 Simple Steps](#) by **Monday, November 27, 2023**.

To receive continuing education (CE) for **WD4520-102623**—Clinician Outreach and Communication Activity (COCA) Calls/Webinars – **Protecting Infants from Respiratory Syncytial Virus (RSV), Thursday, October 26, 2023**, (Web on Demand), please visit [TCEO](#) and follow these [9 Simple Steps](#) between **Tuesday, November 28, 2023**, and **Friday, November 28, 2025**.

Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the **Accreditation Council for Continuing Medical Education (ACCME)**, the **Accreditation Council for Pharmacy Education (ACPE)**, and the **American Nurses Credentialing Center (ANCC)**, to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this activity for a maximum of **1 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1 AAPA Category 1 CME credits**. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation.

CNE: The Centers for Disease Control and Prevention designates this activity for **1 nursing contact hours**.

CPE: The Centers for Disease Control and Prevention designated this **(Knowledge-based)** event for pharmacists to receive **0.1 CEUs** in pharmacy education. The Universal Activity Number is **JA4008229-0000-23-098-L04-P** and enduring **JA4008229-0000-23-099-H04-P**.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer **0.1 CEU's** for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to **1.0 total Category I continuing education contact hours**. Maximum advanced level continuing education contact hours available are **1**. Continuing Competency credits available are **1**. CDC provider number **98614**.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for **1.0 hours** of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer **1 CPH recertification credits** for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

The Emergency Risk Communication Branch in the Division of Emergency Operations, Office of Readiness and Response is responsible for managing all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov

- [CDC Clinician Outreach and Communication Activity Facebook page](#)—connect with COCA on Facebook
- [Clinician Outreach and Communication Activity](#)—resources for healthcare providers
- [COCA RSS Feed](#)—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
- [Crisis & Emergency Risk Communication Training](#)—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
- [Health Alert Network](#)—CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories



CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Links to non-federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organizations.



Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

[Questions or Problems](#) | [Unsubscribe](#)